Why HealthFi Needs Revenue, Not Emissions

In 2022, StepN got millions of people to walk. Then it collapsed, and not because people stopped wanting to walk.

What broke move-to-earn

StepN paid users in its own token. The money for those rewards came from the next cohort of buyers. The reward and the asset were the same object.

So the reward was strongest exactly when it needed to keep growing. Once new buyers slowed, rewards fell, and smaller rewards gave the next cohort less reason to join.

That is not a crypto flaw. It is what happens to any loyalty program funded by its own currency. Airlines learned it slowly. Move-to-earn learned it in eleven months.

The A1C model

A1C does not pay you in A1C. A1C accepts A1C.

Revenue comes from products people already buy: sensors through a clinical channel, A1C Insights subscriptions, 0spike. A portion of that revenue is intended to buy A1C on the open market. Unscheduled, and not pre-announced action by action.

The loop runs in one direction. A user gets healthier, stays subscribed, the business earns, and the token accrues from earnings rather than from the next buyer. No emission has to keep growing. No cohort has to keep arriving. If growth flattens, the mechanism gets smaller. It does not invert.

Why A1C can measure the right thing

A step counter cannot tell whether you are healthier. It can tell whether your phone moved.

A1C measures a glucose response to a real meal on a real day, against your sleep and your stress. That is difficult to fake and worth improving. The outcome gets rewarded, not the attendance.

Where this runs today

A1C Insights ships on iOS and Android across most of the world. The exception is the European Union, where GDPR obligations around health data mean A1C is absent rather than partly compliant.

This is not a roadmap item waiting on a token launch. It is an operating business with a token attached to its economics.

What the next year looks like

The HealthFi narrative will get loud. Most of what arrives under that banner will be a rewards scheme in a health costume, and most of it will unwind the way move-to-earn did.

What survives will be health companies that hold tokens, not tokens that hold a health theme. The test is public: is there revenue, does it come from customers, and does it reach holders.

Disclosures. Forward-looking statements on this page are intentions rather than guarantees, and actual results may differ. Nothing here is an offer to sell or a solicitation to buy any security or token, and nothing here is investment, legal, tax, or medical advice. A1C Insights is not a diagnostic device and does not treat, cure, or prevent disease.